Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multi-Ctr, Prospective, Randomized, Double Blind, Active-Controlled Single Treatment Increasing Dose Trial to Study Safety & Duration of Effect of 40U of PrabotulinumtoxinA-xvfs in Adult Subjects for Treatment of Glabellar Lines

NCT05320393 is registered in ClinicalTrials.gov with Evolus, Inc. as lead sponsor.

NCT NCT05320393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05320393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multi-Ctr, Prospective, Randomized, Double Blind, Active-Controlled Single Treatment Increasing Dose Trial to Study Safety & Duration of Effect of 40U of PrabotulinumtoxinA-xvfs in Adult Subjects for Treatment of Glabellar Lines
Lead sponsor
Evolus, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 30, 2022
Completion date
May 22, 2023
Enrollment
154 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines